Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer

Chen, Feng; Ma, Kai; Zhang, Li; Madajewski, Brian; Turker, Melik Z.; Gallazzi, Fabio; Cruickshank, Kiara; Zhang, Xiuli; Jenjitranant, Pocharapong; Touijer, Karim; Quinn, Thomas P.; Zanzonico, Pat; Wiesner, Ulrich; Bradbury, Michelle S.

doi:10.1021/acsami.9b15195

Cited by 30 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration) with the size decreased by 1.16 nm (from 5.52 to 4.36 nm; Prabhakar et al, 2013). A similar result was observed 48 hr after administration of PEG-coated silica NPs, where the renal clearance increase (from 64% ID to 73% ID) was caused by 2.7 nm decrease (from 6.0 to 3.3 nm) of their size (Chen et al, 2019). Gold nanoparticles also demonstrated size-dependent renal clearance.…”

Section: Enable Renal Clearancesupporting

confidence: 76%

“…It was found that the amount of RGD ligands conjugated to IONPs was 1.32 ± 0.24 mmol/g Fe for uIONPs with a core size of 3 nm comparing to 0.38 ± 0.05 and 0.15 ± 0.01 mmol/g Fe for IONPs with 10 and 20 nm core diameters, respectively (Figure 7f). The high loading with sub‐5 nm nanoparticles can be also applied to carry more signal emitting molecules, such as near infared (NIR) dye Cy5.5 or PET sensitive 64 Cu chelate for PET, for multi‐modal imaging to enhance the sensitivity of the detection (Chen et al, 2019; Ning et al, 2017).…”

Section: Improved Properties and Functionalitiesmentioning

confidence: 99%

See 1 more Smart Citation

Going even smaller: Engineering sub‐5 nm nanoparticles for improved delivery, biocompatibility, and functionality

Xie

Huang

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The rapid development and advances in nanomaterials and nanotechnology in the past two decades have made profound impact in our approaches to individualized disease diagnosis and treatment. Nanomaterials, mostly in the range of 10-200 nm, developed for biomedical applications provide a wide range of platforms for building and engineering functionalized structures, devices, or systems to fulfill the specific diagnostic and therapeutic needs. Driven by achieving the ultimate goal of clinical translation, sub-5 nm nano-constructs, in particular inorganic nanoparticles such as gold, silver, silica, and iron oxide nanoparticles, have been developed in recent years to improve the biocompatibility, delivery and pharmacokinetics of imaging probes and drug delivery systems, as well as in vivo theranostic applications. The emerging studies have provided new findings that demonstrated the unique size-dependent physical properties, physiological behaviors and biological functions of the nanomaterials in the range of the sub-5 nm scale, including renal clearance, novel imaging contrast, and tissue distribution. This advanced review attempts to introduce the new strategies of rational design for engineering nanoparticles with the core sizes under 5 nm in consideration of the clinical and translational requirements. We will provide readers the update on recent discoveries of chemical, physical, and biological properties of some biocompatible sub-5 nm nanomaterials as well as their demonstrated imaging and theranostic applications, followed by sharing our perspectives on the future development of this class of nanomaterials.

show abstract

Section: Enable Renal Clearancesupporting

confidence: 76%

Section: Improved Properties and Functionalitiesmentioning

confidence: 99%

Going even smaller: Engineering sub‐5 nm nanoparticles for improved delivery, biocompatibility, and functionality

Xie

Huang

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…With respect to imaging, renal clearance is a double-edged sword, as rapid clearance will limit time for both passive and active tissue targeting, but will simultaneously reduce background signal and reduce concerns over bioaccumulation, biopersistence and toxicity. For example, "ultrasmall," <10 nm nanoparticles are being investigated as targeted imaging agents that accumulate rapidly in tissues, but also undergo rapid renal elimination, allowing for high signal to noise (F. Chen et al, 2019).…”

Section: Barriers To Tissue Accumulation and Targetingmentioning

confidence: 99%

Challenges in the development of nanoparticle‐based imaging agents: Characterization and biology

Crist

Dasa

Liu

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Despite imaging agents being some of the earliest nanomedicines in clinical use, the vast majority of current research and translational activities in the nanomedicine field involves therapeutics, while imaging agents are severely underrepresented. The reasons for this lack of representation are several fold, including difficulties in synthesis and scale‐up, biocompatibility issues, lack of suitable tissue/disease selective targeting ligands and receptors, and a high bar for regulatory approval. The recent focus on immunotherapies and personalized medicine, and development of nanoparticle constructs with better tissue distribution and selectivity, provide new opportunities for nanomedicine imaging agent development. This manuscript will provide an overview of trends in imaging nanomedicine characterization and biocompatibility, and new horizons for future development. This article is categorized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine

show abstract

“…[2][3][4][5][6] However, only a few of these nanodrug candidates reach the clinical trials. Besides Fe-raheme®, an iron oxide USNP used for chronic kidney disease, only Nanotherm® and Cornell dots 4 have been approved by FDA (Food and Drug Administration) and AGuIX® 5 by ANSM (Agence Nationale de Sécurité du Médicament, French equivalent of FDA), for first-in-human clinical trials in cancer therapy. As pointed out by K. Zarschler et al, 6 one of the main issues limiting the passage in the clinic of these promising nano-objects is the lack of methods allowing their physicochemical characterization, particularly in biological media, to answer regulatory agencies requirements.…”

mentioning

confidence: 99%

Taylor Dispersion Analysis Coupled to Inductively Coupled Plasma-Mass Spectrometry for Ultrasmall Nanoparticle Size Measurement: From Drug Product to Biological Media Studies

et al. 2020

View full text Add to dashboard Cite

During last decade, special focus has been laid on ultrasmall nanoparticles for nanomedicine and eventual clinical translation. To achieve such translation, a lot of challenges have to be solved. Among them, size determination is a particularly tricky one. In this aim, we have developed a simple hyphenation between Taylor dispersion analysis and ICP-MS. This method was proven to allow the determination of the hydrodynamic radius of metal-containing nanoparticles, even for sizes under 5 nm, with a relative standard deviation below 10% (with a 95% confidence interval) and at low concentrations. Moreover, its specificity provides the opportunity to perform measurements in complex biological media. This was applied to the characterization of an ultrasmall gadolinium-containing nanoparticle, used as theranostic agent in cancer diseases. Hydrodynamic radii measured in urine, cerebrospinal fluid and undiluted serum demonstrated the absence of interaction between the particle and biological compounds such as proteins.

show abstract

Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer

Cited by 30 publications

References 44 publications

Going even smaller: Engineering sub‐5 nm nanoparticles for improved delivery, biocompatibility, and functionality

Going even smaller: Engineering sub‐5 nm nanoparticles for improved delivery, biocompatibility, and functionality

Challenges in the development of nanoparticle‐based imaging agents: Characterization and biology

Taylor Dispersion Analysis Coupled to Inductively Coupled Plasma-Mass Spectrometry for Ultrasmall Nanoparticle Size Measurement: From Drug Product to Biological Media Studies

Contact Info

Product

Resources

About